PCMA President releases statement on new Medicare Part D study

Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement today on a new study published in the Journal of the American Medical Association that found "implementation of Medicare Part D was followed by a significant reductions in nondrug medical spending, particularly on acute and post acute care, for elderly Medicare beneficiaries with limited prior drug coverage".

"This study is a potential 'game-changer' and shows how better prescription drug benefits can generate significant savings in other health care settings.  Many illnesses, hospitalizations, and emergency room visits occur because seniors with sub-par benefits didn't have access to the medications they needed.  The Part D example shows that more competition and greater use of PBM tools like home delivery of chronic refills can help address this issue.

"As Medicaid's top-down, fee-for-service approach to pharmacy is bankrupting states across America, Part D is a success story which comes in under budget each year.  Part D has expanded access to prescription drugs and reduced medical costs thanks to the use of modern pharmacy benefit management tools.

"According to a recent report, the states and the federal government could save $33 billion – without cutting benefits for patients or payments to doctors and hospitals – by bringing pharmacy benefits into the 21st century.

"Policymakers should follow the lead of Governors Cuomo, Christie and others who are re-shaping Medicaid pharmacy to operate more like Part D and reject proposals that re-shape Part D in the image of the failed Medicaid program."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vial size could save Medicare millions on Alzheimer's drug